US 11,806,277 B2
Intravitreal injection device with combined vitreous sampling
Alexandre Tumlinson, South San Francisco, CA (US); and Ellen Kaplan, South San Francisco, CA (US)
Assigned to TWENTY TWENTY THERAPEUTICS LLC, South San Francisco, CA (US)
Filed by Twenty Twenty Therapeutics LLC, South San Francisco, CA (US)
Filed on May 13, 2021, as Appl. No. 17/319,742.
Claims priority of provisional application 63/024,725, filed on May 14, 2020.
Prior Publication US 2021/0353455 A1, Nov. 18, 2021
Int. Cl. A61F 9/00 (2006.01); A61M 5/315 (2006.01); A61M 5/19 (2006.01); A61M 5/32 (2006.01); A61F 9/007 (2006.01); A61M 5/31 (2006.01)
CPC A61F 9/0008 (2013.01) [A61F 9/00736 (2013.01); A61F 9/00781 (2013.01); A61M 5/19 (2013.01); A61M 5/31501 (2013.01); A61M 5/32 (2013.01); A61M 2005/3126 (2013.01); A61M 2210/0612 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An injection and extraction ophthalmic device, comprising:
a housing for receiving:
an injectant chamber configured to store an injectant;
a plunger disposed within the injectant chamber; and
a stopper coupled to a distal portion of the plunger;
a hypodermic needle disposed at a distal end of the housing; and
a sample chamber located adjacent to the distal end of the housing, wherein the housing, the hypodermic needle, and the sample chamber are arranged such that:
the sample chamber is configured to receive material via the hypodermic needle in response to movement of the stopper to a first depth within the housing; and
when the stopper is moved to a second depth within the housing exceeding the first depth, the injectant chamber is configured to dispense the injectant through the hypodermic needle;
wherein the sample chamber is configured to stop receiving any of the material when the injectant chamber is dispensing the injectant, and wherein the injectant chamber does not dispense any of the injectant when the sample chamber is receiving the material.